TY - JOUR
T1 - Disparities in Lung Cancer Treatment
AU - Harrison, Sharon
AU - Judd, Julia
AU - Chin, Sheray
AU - Ragin, Camille
N1 - Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2022/2
Y1 - 2022/2
N2 - Purpose of Review: Despite an overall reduction in lung cancer incidence and mortality rates worldwide, Blacks still have higher mortality rates compared to Whites. There are many factors that contribute to this difference. This review seeks to highlight racial disparities in treatment and the possible reasons for these disparities. Recent Findings: Factors attributing to racial disparities in lung cancer treatment include social determinants of health, differences in the administration of guideline-concordant therapy as well as molecular testing that is essential for most NSCLC patients. Summary: One way to circumvent disparities in lung cancer survivorship is to ensure equal representation of race in research at all levels that will provide insight on interventions that will address social determinants of health, differences in treatment patterns, molecular testing, and clinical trial involvement.
AB - Purpose of Review: Despite an overall reduction in lung cancer incidence and mortality rates worldwide, Blacks still have higher mortality rates compared to Whites. There are many factors that contribute to this difference. This review seeks to highlight racial disparities in treatment and the possible reasons for these disparities. Recent Findings: Factors attributing to racial disparities in lung cancer treatment include social determinants of health, differences in the administration of guideline-concordant therapy as well as molecular testing that is essential for most NSCLC patients. Summary: One way to circumvent disparities in lung cancer survivorship is to ensure equal representation of race in research at all levels that will provide insight on interventions that will address social determinants of health, differences in treatment patterns, molecular testing, and clinical trial involvement.
KW - Black-White disparity
KW - Chemotherapy
KW - Clinical trials
KW - Guideline-concordant treatment
KW - Molecular biomarker testing utilization
KW - Next-generation sequencing
KW - Non-small cell lung cancer
KW - Racial disparities
KW - Radiation and surgery
KW - Social determinants of health
UR - http://www.scopus.com/inward/record.url?scp=85123586704&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000751954400001&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.1007/s11912-022-01193-4
DO - 10.1007/s11912-022-01193-4
M3 - Review article
C2 - 35080738
SN - 1523-3790
VL - 24
SP - 241
EP - 248
JO - Current Oncology Reports
JF - Current Oncology Reports
IS - 2
ER -